Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Blood Cancer Journal|October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analysesLaahn Foster, Larry D Anderson, Alfred Chung, et al.
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
Leukemia Research|July 31, 2007
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemiaRebekah L Browning, Susan M Geyer, Amy J Johnson, et al.
Blood|March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyMyron S Czuczman, Luis Fayad, Vincent Delwail, et al.
Blood|November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabFarrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Blood|November 5, 2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaMitch A Phelps, Thomas S Lin, Amy J Johnson, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemiaShih-Shih Chen, Aparna Raval, Amy J Johnson, et al.
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Blood|February 5, 2009
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivoDavid M Lucas, Ryan B Edwards, Gerard Lozanski, et al.
Pageof 9